Tenaya Therapeutics (TNYA) Other Non-Current Liabilities (2020 - 2026)
Tenaya Therapeutics' (TNYA) quarterly Other Non-Current Liabilities came in at $418000.0 in Q1 2026, up 45.64% year-on-year from $287000.0 in Q1 2025, and up 1.95% quarter-over-quarter from $410000.0 in Q4 2025.
Tenaya Therapeutics (TNYA) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $418000.0 for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 45.64% year-over-year to $418000.0 in Q1 2026; TTM through Mar 2026 was $418000.0, a 45.64% increase from a year earlier, with the FY2025 full-year figure at $410000.0, up 45.91% from the prior year.
- Other Non-Current Liabilities climbed to $418000.0 in Q1 2026 per TNYA's latest filing, from $410000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $418000.0 in Q1 2026 and bottomed at $212000.0 in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $259000.0 (2024), against an average of $273176.5.
- Across the five-year window, Other Non-Current Liabilities soared 7133.33% in 2022 and increased 9.06% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $228000.0 in 2022, then increased by 10.96% to $253000.0 in 2023, then climbed by 11.07% to $281000.0 in 2024, then soared by 45.91% to $410000.0 in 2025, then increased by 1.95% to $418000.0 in 2026.
- Per Business Quant, the three latest TNYA Other Non-Current Liabilities figures stand at $418000.0 (Q1 2026), $410000.0 (Q4 2025), and $301000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Tenaya Therapeutics | 167.00 Mn | 167.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 418,000.00 |
| Dec 31, 2025 | 410,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | 287,000.00 |
| Dec 31, 2024 | 281,000.00 |
| Sep 30, 2024 | 276,000.00 |
| Jun 30, 2024 | 266,000.00 |
| Mar 31, 2024 | 259,000.00 |
| Dec 31, 2023 | 253,000.00 |
| Sep 30, 2023 | 246,000.00 |
| Jun 30, 2023 | 240,000.00 |
| Mar 31, 2023 | 234,000.00 |
| Dec 31, 2022 | 228,000.00 |
| Sep 30, 2022 | 223,000.00 |
| Jun 30, 2022 | 217,000.00 |
| Mar 31, 2022 | 212,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | 96,000.00 |
| Jun 30, 2021 | 3,000.00 |